RISFAX November 16, 2018
日本語- AstraZeneca to grow by “annual launch” of new drugs despite adverse wind, a possible option for increasing MRs
- Health minister Nemoto: Though shared at Central Social Insurance Medical Council (Chuikyo), October revision “has not been decided”
- Director general Miyamoto of Pharmaceutical Safety and Environmental Health Bureau: Exception to general marketing compliance officer; possible utilization of “people who received pharmaceutical education”
- MHLW subcommittee: A voice seeking a clinical trial leading to approval of intraperitoneal administration of PACLITAXEL
- CMIC HD president Oishi: Acquisition of “PVC (pharmaceutical value creator) deals” as a key project in the new mid-term plan
- Towa to launch the hair growth agent “MINOUP” on Nov. 21, but denying full entry into OTC drugs business
- AstraZeneca initiates translation of protocols using AI, “Three weeks down to 30 seconds”
- Japan Pharmaceutical Manufacturers Association (JPMA) resumes support for dispatch of MHLW officials to New York Office of JETRO
- Professor Yamanaka of Tokyo Women’s Medical University: Significance of biosimilars (BS) is expanded access for “sustainable treatment”
- Nippon Pharmacy Association (NPhA) announces “challenging” objective setting
- Mitsubishi Tanabe survey: “I can read Doshomachi”, 13.5% of people in their 20’s
- ◆Note◆ Forum to learn patient-centric healthcare